MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.76 0.73

Overview

Share price change

24h

Current

Min

2.51

Max

2.83

Key metrics

By Trading Economics

Income

-6.4M

-53M

Sales

-9.6M

47M

Profit margin

-112.813

Employees

580

EBITDA

-28M

-49M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+51.09% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

175M

950M

Previous open

2.03

Previous close

2.76

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

9 Jul 2025, 15:46 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 Jul 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 Jul 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 Jul 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 Jul 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 Jul 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 Jul 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jul 2025, 20:26 UTC

Earnings

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 Jul 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 Jul 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 Jul 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 Jul 2025, 17:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 Jul 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 Jul 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jul 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 Jul 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 Jul 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 Jul 2025, 16:14 UTC

Acquisitions, Mergers, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 Jul 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 Jul 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 Jul 2025, 15:31 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250M Private Placement

9 Jul 2025, 15:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 Jul 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 Jul 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 Jul 2025, 14:31 UTC

Acquisitions, Mergers, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 Jul 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 Jul 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

51.09% upside

12 Months Forecast

Average 4.17 USD  51.09%

High 7 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

4

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.